when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY & Co ($LLY) · catalysts · pharmadog

← back to ELI LILLY & Co

Catalysts for $LLY

78 tracked

ELI LILLY & Co earnings

ELI LILLY & Co earnings

ELI LILLY & Co earnings

FOUNDAYO (ORFORGLIPRON CALCIUM) — FDA approval

orforglipron calcium

TRULICITY (DULAGLUTIDE) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

MOUNJARO (TIRZEPATIDE) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

MOUNJARO (TIRZEPATIDE) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

MOUNJARO (TIRZEPATIDE) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

EBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approval

OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval

INLURIYO (IMLUNESTRANT TOSYLATE) — FDA approval

imlunestrant tosylate

MOUNJARO (TIRZEPATIDE) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

MOUNJARO (TIRZEPATIDE) — FDA approval

TRULICITY (DULAGLUTIDE) — FDA approval

EBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval

OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval

ZEPBOUND (TIRZEPATIDE) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

MOUNJARO (TIRZEPATIDE) — FDA approval

← prevpage 1 of 3next →

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%

$LLY1244.40-2.81%